Baudax Bio Inc. [NASDAQ: BXRX] jumped around 0.01 points on Tuesday, while shares priced at $0.24 at the close of the session, up 5.13%. The company report on January 4, 2022 that Baudax Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference.
Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the H.C. Wainwright BIOCONNECT Virtual Conference being held January 10 – 13, 2022.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
The presentation will be made available for on-demand listening beginning Monday, January 10, 2022 at 7:00 a.m. Eastern Time and may be accessed on the “Events” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. A replay will be available on the Baudax Bio website for a period of 30 days following the event.
Baudax Bio Inc. stock is now 10.31% up from its year-to-date (YTD) trading value. BXRX Stock saw the intraday high of $0.2805 and lowest of $0.2217 per share. The company’s 52-week high price is 2.12, which means current price is +10.92% above from all time high which was touched on 01/04/22.
Compared to the average trading volume of 1.56M shares, BXRX reached a trading volume of 35527306 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Baudax Bio Inc. [BXRX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BXRX shares is $2.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BXRX stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JMP Securities have made an estimate for Baudax Bio Inc. shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on May 15, 2020.
The Average True Range (ATR) for Baudax Bio Inc. is set at 0.03, with the Price to Sales ratio for BXRX stock in the period of the last 12 months amounting to 26.08.
How has BXRX stock performed recently?
Baudax Bio Inc. [BXRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.62. With this latest performance, BXRX shares dropped by -26.77% in over the last four-week period, additionally sinking by -65.05% over the last 6 months – not to mention a drop of -75.82% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BXRX stock in for the last two-week period is set at 30.54, with the RSI for the last a single of trading hit 30.95, and the three-weeks RSI is set at 31.20 for Baudax Bio Inc. [BXRX]. The present Moving Average for the last 50 days of trading for this stock 0.4070, while it was recorded at 0.2276 for the last single week of trading, and 0.6858 for the last 200 days.
Baudax Bio Inc. [BXRX]: Deeper insight into the fundamentals
Baudax Bio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.90 and a Current Ratio set at 2.20.
Insider trade positions for Baudax Bio Inc. [BXRX]
There are presently around $2 million, or 11.40% of BXRX stock, in the hands of institutional investors. The top three institutional holders of BXRX stocks are: VANGUARD GROUP INC with ownership of 3,740,262, which is approximately 0.334% of the company’s market cap and around 0.90% of the total institutional ownership; BLACKROCK INC., holding 1,329,684 shares of the stock with an approximate value of $0.31 million in BXRX stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $0.16 million in BXRX stock with ownership of nearly 27.291% of the company’s market capitalization.
9 institutional holders increased their position in Baudax Bio Inc. [NASDAQ:BXRX] by around 635,137 shares. Additionally, 18 investors decreased positions by around 655,749 shares, while 13 investors held positions by with 6,032,034 shares. The mentioned changes placed institutional holdings at 7,322,920 shares, according to the latest SEC report filing. BXRX stock had 2 new institutional investments in for a total of 82,961 shares, while 9 institutional investors sold positions of 232,175 shares during the same period.